Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience.

Date publication

janvier 2014

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MUNZER Martine

Tous les auteurs :
Pasquet M, Aladjidi N, Guiton C, Courcoux MF, Munzer M, Auvrignon A, Lutz P, Ducassou S, Leroy G, Munzer C, Leverger G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24152194

Résumé

A minority of children with chronic immune thrombocytopenia (ITP) require therapeutic intervention to prevent haemorrhagic risk. This retrospective national study evaluated romiplostim in childhood non-responsive or refractory chronic ITP. Between 2009 and 2012, 10 patients whose Buchanan score was 3-4 were treated with romiplostim. The median duration of thrombocytopenia was 1.9 years (0.8-15). The median duration of romiplostim treatment was 9 months (3-36). A response was observed in 5/10 patients (one complete, four partial). No serious adverse effect was noticed. The long-term benefit/risk balance of this innovative treatment is currently recorded by Centre de Reference National des Cytopenies Auto-immunes de l'Enfant.

Référence

Br J Haematol. 2014 Jan;164(2):266-71